Form 4: Hologic President's Stock Activity, RSU Grant

Hologic's President of Diagnostic Solutions, Jennifer M. Schneiders, reported recent stock transactions including the acquisition of restricted stock units and shares withheld for tax obligations.

Summary

• Jennifer M. Schneiders, President of Diagnostic Solutions at Hologic Inc., reported changes in her beneficial ownership of common stock.
• On November 7, 2025, 158 shares were disposed of at $74.1 per share to cover tax obligations related to restricted stock unit settlement.
• On November 10, 2025, 30,282 restricted stock units (RSUs) were acquired. These RSUs will vest in equal installments over three years starting from the grant date.
• On November 11, 2025, an additional 702 shares were disposed of at $74.6 per share for tax withholding purposes.
• Following these transactions, Ms. Schneiders beneficially owns 41,879 shares of Hologic common stock.
• The reported beneficial ownership includes 361 shares acquired through the company's employee stock purchase plan since the last Form 4 filing.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the significant grant of restricted stock units, which aligns the executive's interests with long-term shareholder value, despite routine tax-related share disposals.

Positives

• Acquisition of 30,282 restricted stock units (RSUs) on November 10, 2025, indicating continued equity incentive for management and aligning executive interests with long-term shareholder value.
• Inclusion of 361 shares acquired via the Employee Stock Purchase Plan (ESPP) since the last filing, demonstrating ongoing employee investment in the company.

Negatives

• Disposal of 158 shares at $74.1 and 702 shares at $74.6 for tax obligations, which reduces direct share ownership, though this is a standard practice for RSU vesting.

Future Outlook

The acquired restricted stock units are scheduled to vest in equal installments on the first three anniversaries of the November 10, 2025 grant date, indicating future equity compensation for the executive.

Industry Context

This filing reflects routine insider stock activity for an executive at a publicly traded medical technology company, common for compensation and tax planning purposes within the industry.

Related Party Transactions

• Jennifer M. Schneiders, President of Diagnostic Solutions, engaged in stock transactions with Hologic Inc., including the acquisition of restricted stock units and the disposal of shares for tax obligations, which are considered related party dealings.

Stakeholder Impact

• Shareholders: Increased alignment of executive's long-term interests with shareholders due to the RSU grant. Routine tax-related share disposals have minimal impact on overall share float.
• Employees: The mention of the Employee Stock Purchase Plan (ESPP) indicates ongoing opportunities for broader employee ownership.

Next Steps

• First installment of the 30,282 restricted stock units will vest on November 10, 2026.
• Second installment of the 30,282 restricted stock units will vest on November 10, 2027.
• Third installment of the 30,282 restricted stock units will vest on November 10, 2028.

Key Dates

Keywords

Hologic Inc, HOLX, Jennifer M. Schneiders, Insider Trading, Form 4, Restricted Stock Units, RSU, Stock Transactions, Employee Stock Purchase Plan, ESPP, Beneficial Ownership